New paclitaxel-cisplatin based chemotherapy regimen for advanced stage, recurrent, or refractory neuroblastoma—preliminary report
Corresponding Author
Giammarco Surico MD
Department of Pediatric Hematology and Oncology, II Pediatric Clinic, University of Bari, Bari, Italy
Sezione di Onco, Ematologia Pediatrica, II Clinica Pediatrica, Policlinico, Piazza Giulio Cesare, 11 70124, Bari, Italy.Search for more papers by this authorPaola Muggeo MD
Department of Pediatric Hematology and Oncology, II Pediatric Clinic, University of Bari, Bari, Italy
Search for more papers by this authorFrancesco De Leonardis MD
Department of Pediatric Hematology and Oncology, II Pediatric Clinic, University of Bari, Bari, Italy
Search for more papers by this authorNicola Rigillo MD
Department of Pediatric Hematology and Oncology, II Pediatric Clinic, University of Bari, Bari, Italy
Search for more papers by this authorCorresponding Author
Giammarco Surico MD
Department of Pediatric Hematology and Oncology, II Pediatric Clinic, University of Bari, Bari, Italy
Sezione di Onco, Ematologia Pediatrica, II Clinica Pediatrica, Policlinico, Piazza Giulio Cesare, 11 70124, Bari, Italy.Search for more papers by this authorPaola Muggeo MD
Department of Pediatric Hematology and Oncology, II Pediatric Clinic, University of Bari, Bari, Italy
Search for more papers by this authorFrancesco De Leonardis MD
Department of Pediatric Hematology and Oncology, II Pediatric Clinic, University of Bari, Bari, Italy
Search for more papers by this authorNicola Rigillo MD
Department of Pediatric Hematology and Oncology, II Pediatric Clinic, University of Bari, Bari, Italy
Search for more papers by this author
REFERENCES
- 1 Brodeur GM, Castleberry RP. Neuroblastoma. In: PA Pizzo, DG Poplack, editors. Principles and practice of pediatric oncology. Philadelphia: JB Lippincott Company; 1993, p 739–767.
- 2 WP McGuire, EK Rowinsky, editors. Paclitaxel in cancer treatment. New York: Marcel Dekker, Inc.; 1995, p 201–305.
- 3 Riccardi A, Servidei T, Tornesello A, et al. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. Eur J Cancer 1995; 31A: 494–499.
- 4 Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9: 1692–1703.
- 5 Rose PG, Blessing JA, Gershenson DM, et al. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 1999; 17: 2676–2680.
- 6 Hurwitz CA, Relling MV, Weitman SD, et al. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. J Clin Oncol 1993; 11: 2324–2329.
- 7 Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15: 187–192.
- 8 Sonnichsen DS, Hurwitz CA, Pratt CB, et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994; 12: 532–538.
- 9 Helson L, Helson C, Malik S, et al. A saturation threshold for taxol cytotoxicity in human glial and neuroblastoma cells. Anticancer Drugs 1993; 4: 487–490.
- 10 Fizazi K, Zelek L. Is one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. Ann Oncol 2000; 11: 133–149.
